Iskra Pusic, MD, Washington University in St. Louis, St. Louis, MO, talks on the evolution of the criteria used to designate stem cell transplant eligibility for patients with hematological malignancies. Dr Pusic explains that in the past 10 years, improved transplantation techniques have enabled better prevention and management of post-transplantation complications, such as graft-versus-host disease (GvHD), and better supportive care post-transplantation. Importantly, the population that is eligible for haploidentical transplant has substantially increased. Dr Pusic also explains how recent developments in algorithms taking into account comorbidities are helpful for the evaluation of patient eligibility. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

свернуть